18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
复制标题
DOI：
10.2967/jnumed.108.054205
复制
发表时间：
2009-01-01
影响因子：
9.3
通讯作者：
Ell, Peter
中科院分区：
文献类型：
--
作者：
Ben-Haim, Simona;Ell, Peter
多模态成像，其最大的代表，PET/CT，有一个坚定的地方，在评估病人提出的癌症。有了F-18-FDG，PET/CT正迅速成为癌症复发分期和评估的关键研究工具。在过去的5年中，PET/CT也被广泛接受为用于证明干预和治疗早期反应的关键工具。在这种情况下，F-18-FDG PET/CT正在解决一个主要的临床需求，因为其固有的能力，以证明（在其他标志物的反应），如果疾病的修改已经发生。本综述提供了这方面的现有证据。
Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With F-18-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with F-18-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.